Anti-herpes activity of adenine arabinoside monophosphate.
Adenine arabinoside monophosphate (Ara-AMP) demonstrated antiviral activity equivalent to adenine arabinoside (Ara-A) against herpesvirus Types 1 and 2 in tissue culture. Against established herpes virus Type 1 epithelial keratitis in rabbits, Ara-AMP 2 per cent was comparable in efficacy to Ara-A 3 per cent, and Ara-AMP 20 per cent was superior to Ara-A 3 per cent. These results are especially significant in that Ara-A's high solubility will permit (1) more concentrated formulations to be presented topically and (2) adequate absorption by parenteral routes with smaller fluid loads than required for Ara-A.
D000249:Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000287:Administration, Topical; D000818:Animals; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006564:Herpesviridae / Q000187:drug effects*; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D011684:Purine Nucleosides / Q000627:therapeutic use*; D011817:Rabbits; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use*
D011684:Purine Nucleosides; D000249:Adenosine Monophosphate; D014740:Vidarabine